A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis.
An open randomized study for comparing the efficacy of albendazole and thiabendazole in chronic strongyloidiasis was done in 1990-1992. All 35 patients with positive stool examinations for Strongyloides stercoralis were divided randomly into two groups. 23 patients (group A) received albendazole (400 mg twice daily for 5 days) and 12 patients (group B) received thiabendazole (1 g twice daily for 5 days). All patients except four patients in group A were admitted in the Hospital for Tropical Diseases for 21 days for monitoring side effects (D0-7) and stool examination (D0, D7, 8, 9, D21, 22, 23). Methods of stool examination included: direct microscopy of saline smear, formalin ether concentration, culture (Harada and Mori method) and larva count (Stool and Sasa method). Cure was defined as negative stool examination done at 21 days after medication by all above methods. The cure rate for group A was 95% (only one failed to clear the parasite at D21) and the cure rate for group B was 100%. But there was no statistical difference between the two. Mild changes of transminases observed in 5/23 patients who received albendazole, but none developed clinical hepatitis.
Pitisuttithum
P
P
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Supanaranond
W
W
Chindanond
D
D
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000969:Antinematodal Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004804:Eosinophils; D005243:Feces / Q000469:parasitology; D006801:Humans; D007958:Leukocyte Count; D010270:Parasite Egg Count; D013322:Strongyloidiasis / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D013827:Thiabendazole / Q000627:therapeutic use*
D000969:Antinematodal Agents; D015766:Albendazole; D013827:Thiabendazole